檢索結果 - Paul Alabanza
- Showing 1 - 2 results of 2
-
1
Molnupiravir, an Oral Antiviral Treatment for COVID-19 由 William A. Fischer, Joseph J. Eron, Wayne Holman, Myron S. Cohen, Lei Fang, Laura J. Szewczyk, Timothy P. Sheahan, Ralph S. Baric, Katie R. Mollan, Cameron R. Wolfe, Elizabeth R. Duke, Masoud Azizad, Katyna Borroto–Esoda, David A. Wohl, Amy James Loftis, Paul Alabanza, Felicia Lipansky, Wendy Painter
出版 2021Pré-impressão -
2
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus 由 William A. Fischer, Joseph J. Eron, Wayne Holman, Myron S. Cohen, Lei Fang, Laura J. Szewczyk, Timothy P. Sheahan, Ralph S. Baric, Katie R. Mollan, Cameron R. Wolfe, Elizabeth R. Duke, Masoud Azizad, Katyna Borroto–Esoda, David A. Wohl, Robert W. Coombs, Amy James Loftis, Paul Alabanza, Felicia Lipansky, Wendy Painter
出版 2021Artigo
相關主題
Coronavirus disease 2019 (COVID-19)
Disease
Infectious disease (medical specialty)
Internal medicine
Medicine
Virology
2019-20 coronavirus outbreak
Adverse effect
Alternative medicine
Clinical endpoint
Clinical trial
Coronavirus
Immunology
Outbreak
Pathology
Placebo
Randomized controlled trial
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Tolerability
Virus